Researchers conducted a meta-analysis to determine the incidence of adverse events among patients assigned to placebo-receiving groups in randomized clinical trials.
A review of DBBR data demonstrated that regular recreational physical activity may reduce the risk of all-cause and cancer-specific mortality in persons who are habitually active as a lifestyle as well as those who adopt regular exercise as a lifestyle after diagnosis.
Mean changes in hematologic indices found similar regardless of same-day or prior administration of B12 supplementation in patients receiving pemetrexed for NSCLC or pleural mesothelioma.
In this retrospective study, researchers sought to determine the efficacy of nedaplatin vs cisplatin for the treatment of malignancy-induced malignant pleural effusion.
An international team reviews osimertinib-associated dermatologic adverse events in patients treated with the third-generation EGFR-TKI.
In a randomization of women with early-stage breast cancer, researchers explored the potential benefits of chemotherapy for women whose Oncotype DX RS was midrange.
Four of 9 lung cancer screening models were shown to effectively select the most appropriate candidates for low-dose CT lung cancer screening among US ever-smokers.
In updating its 2012 recommendations, the US Preventive Services Task Force changes its stance on PSA-based screening for prostate cancer in men older than 50. The new guidelines advocate for a patient-physician discussion of the benefits of testing vs the potential harms.
A new US Preventive Services Task Force Evidence Report is suggesting that greater efforts are needed to educate children and young adults with fair skin about risks of sun exposure. Although the Task Force recommendations are directed at primary care, its members are encouraging oncology nurses to take note of these new findings.
A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.